Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
AMD looks like a buyable supply position after a sharp July pullback. The company has a dominant presence across CPUs, accelerators and adaptive SoCs, a healthy balance sheet, and meaningful free cash flow. This trade targets a rebound toward the $560 area over a mid-term 45 trading-day horizon while managing risk with a $420 stop.
NeurAxis, a US-based medical technology company specializing in neuromodulation therapies, reported record financial results for Q2 2026, showing a 116% year-over-year revenue increase to $1.9 million. This growth was driven by a Category I CPT code assignment effective January 2026, which expanded payer coverage and increased full reimbursement sa…
Fennec Pharmaceuticals announced its Q2 2026 financial results showing a 78% year-over-year increase in net product sales to $17.1 million and a positive non-GAAP adjusted EBITDA of $2.8 million. The company highlighted record demand for its FDA-approved therapy PEDMARK®, designed to reduce cisplatin-induced ototoxicity in pediatric cancer patients…
AC Immune SA announced that the FDA granted Fast Track designation and approved its Investigational New Drug (IND) application for ACI-7104, an active immunotherapy targeting alpha-synuclein aggregates in early-stage Parkinson’s disease. Positive interim Phase 2 data demonstrated safety, tolerability, and immunogenicity, supporting further clinical…
Gain Therapeutics reported Q2 2026 financial results and provided updates on its Parkinson’s disease drug rexaceract, which received FDA IND clearance allowing Phase 2 trials to start in Q3 2026. Clinical data from the ongoing Phase 1b extension indicated durable benefits for patients, especially those with high baseline cerebrospinal fluid glucosy…
Prelude Therapeutics reported their Q2 2026 financial results highlighting significant progress in advancing their oncology pipeline. The company plans to initiate a Phase 1 clinical trial for PRT13722, a selective KAT6A degrader targeting HR+ breast cancer, in Q4 2026. Enrollment continues in the Phase 1 trial of PRT12396, a mutant-selective JAK2V…
Beamr Imaging Ltd. issued a CEO letter highlighting its expansion into the autonomous vehicle (AV) market by initiating its first structured engagements and integrating its AI-optimized video compression technology into AV platforms. The company continues to enhance its media and entertainment business, exemplified by large-scale deployments such a…
CalciMedica, a clinical-stage biopharmaceutical company, announced a $49 million private placement financing to advance its pulmonary hypertension (PH) program, including a Phase 1b proof-of-concept trial for Auxora in pulmonary arterial hypertension (PAH) and IND submission for oral CRAC inhibitor CM5480, both expected mid-2027. The FDA has aligne…
Aura Biosciences announced the full enrollment of its Phase 3 CoMpass trial with 108 patients, exceeding targets and on track for topline data in the second half of 2027, advancing development of belzupacap sarotalocan (bel-sar) for ocular cancers. The company is strategically concentrating resources on ocular oncology programs while deprioritizing…
Tango Therapeutics reported a strong Q2 2026 financial update highlighting encouraging Phase 1/2 clinical data for its cancer drug vopimetostat in combination with daraxonrasib for MTAP-deleted, RAS-mutant pancreatic cancer. The combination achieved a 92% objective response rate and 90% six-month progression-free survival, positioning it for late-s…
Beyond Meat announced a 1-for-30 reverse stock split of its common shares effective August 13, 2026, to meet Nasdaq minimum bid price requirements and maintain its Nasdaq Global Select Market listing. The split adjusts shares, authorized share counts, convertible notes, warrants, and equity awards proportionately, without changing shareholder owner…
Brazil Potash Corp. announced that Brazil's Federal Regional Court of the 1st Region reaffirmed the legitimacy of the consultation process with the Mura Indigenous people, upheld the authority of the Amazonas Environmental agency to license the Autazes potash project, and blocked appeals to higher courts. These rulings strengthen the legal foundati…
CVRx, Inc., a medical device company specializing in neuromodulation for cardiovascular diseases, announced a leadership change in its sales department. Robert John, the Chief Revenue Officer, is departing, and Paul Verrastro will serve as Interim Head of Sales while a search for a permanent replacement is underway. Verrastro brings over 30 years o…
Ridgepost Capital, a NYSE-listed private markets solutions provider managing over $50 billion in assets, announced its sponsorship at IPEM Global 2026 in Paris. Key executives and representatives from its investment strategies will attend to engage with peers and clients, highlighting the firm's capabilities in private equity, private credit, and v…
Americold Realty Trust is enhancing its temperature-controlled logistics network to support the growing direct-to-consumer and omnichannel food sector by offering integrated cold chain fulfillment solutions. Leveraging infrastructure, technology like their SmarTrakr™ platform, and operational expertise, Americold is enabling brands such as Good Ran…
Legend Biotech Corporation reported strong second quarter 2026 results highlighted by a 50% increase in net trade sales of CARVYKTI to approximately $657 million, expanded global availability, and positive clinical proof-of-concept data for its in vivo CAR-T therapy LB2501. The company strengthened its balance sheet with a $212 million public offer…
etoro Group Ltd. announced an agreement to acquire TradeZero, a US-based online brokerage for active traders, for up to $231 million in cash and shares. The deal will enhance etoro's US market presence by adding TradeZero's advanced trading platforms, broker-dealer infrastructure, and access to Canadian markets. The acquisition is expected to be ac…
etoro Group Ltd. reported robust second quarter 2026 results with net contribution up 9% year-over-year to $229 million and funded accounts increasing 18% to 4.28 million. The company launched new AI-driven mobile app features and expanded its digital asset offerings, including self-custody and on-chain finance products. etoro also announced the ac…
Kailera Therapeutics has named Nur Nicholson as Chief Technology Officer effective August 31, 2026. Nicholson brings extensive experience in global technical operations and manufacturing, aiding Kailera's advancement of its lead obesity drug candidate, ribupatide injection, through Phase 3 trials and preparations for commercialization. The appointm…
Baker Hughes has been awarded a multi-year contract by Kuwait Oil Company to collaborate as a key technology partner in the Ahmadi Innovation Valley project. The focus is on deploying digital and AI-based automation solutions to optimize upstream oil and gas production, with Baker Hughes committing to establish a dedicated R&D center in Kuwait to s…
Autolus Therapeutics announced substantial revenue growth in Q2 2026 with net product revenue from AUCATZYL increasing 119% YoY to $45.7 million. The company raised its 2026 revenue guidance to $140-$150 million and strengthened its capital base through a $250 million credit facility. Clinical development programs for AUCATZYL in autoimmune disease…
Enviri Corporation announced its second quarter 2026 financial results, highlighting strong performance in its Harsco Environmental and Rail divisions. The company strategically exited two European Harsco Rail ETO contracts to eliminate future execution risks. While GAAP results showed a large consolidated loss primarily due to contract exit charge…
Sono-Tek Corporation announced receiving its largest-ever purchase order for a single integrated production line valued at over $3.6 million. The order, from an existing customer scaling up medical diagnostic device manufacturing, marks a transition from process development to high-volume production using Sono-Tek's ultrasonic coating technology co…
Harvard Bioscience, Inc. reported strong second quarter 2026 financial results with revenues increasing 11% year-over-year to $22.7 million. The company raised its full-year 2026 revenue guidance to 3%-5% growth reflecting solid demand across its telemetry, cellular and molecular technology products, and continued operational improvements. Despite …
Broadwind, Inc. (Nasdaq: BWEN) announced its Q2 2026 financial results, highlighting a 67% year-over-year increase in total revenue driven by growth in its Gearing and Industrial Solutions segments. The company completed its strategic exit from wind fabrications by selling its Texas facility, refocusing as a pure-play precision manufacturer serving…
